Tenascin-C expression in prostatic intraepithelial neoplasia (PIN): A marker of progression?

Anticancer Research

Volumn 18, Issue 4 A, 1998, Pages 2679-2684

  Xue, Yong ^a   Smedts, Frank ^b   Latijnhouwers, Mieke Ahe ^a   Ruijter, Emiel Th ^a   Aalders, Tilly W ^a   De La Rosette, Jean J M C H ^a   Debruyne, Frans M J ^a   Schalken, Jack A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Foundation of Collaborating Hospital   (Netherlands)

Author keywords

Premalignant; Prostate; Stromal epithelial interactions; Tenascin; Tissue remodelling

Indexed keywords

TENASCIN; TUMOR MARKER;

ARTICLE; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA;

CARCINOMA IN SITU; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TENASCIN; TUMOR MARKERS, BIOLOGICAL;

EID: 0031837131     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Celi 61: 759-767, 1990.
2. Bostwick DG: High grade prostatic intraepithelial neoplasi - the most likely precursor of prostate cancer. Cancer 75: 1823-1836, 1995.
3. Bostwick DG, Pacelli A, and Lopez Beltran A: Molecular biology of prostatic intraepithelial neoplasia. Prostate 29: 117-134, 1996.
4. Sakr WA, Haas GP, Cassin BF, Pontes JE, and Crissman JD: The frequency of carcinoma and intraepithelial neoplasia ofthe prostate in young male patients. J Urol 150: 379-385, 1993.
5. Stone E: Prostatic intraepithelial neoplasia: will it help doctors pinpoillt early prostate cancer? J Natl Cancer Inst 88: 1023-1024, 1996.
6. Haggman MJ, Macoska JA, Wojno KJ, and Oesterling JE: The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J Urol 158: 12-22, 1997.
7. Schenk S and Chiquet Ehrismann R: Tenascins. Methods Enzymol 245: 52-61, 1994.
8. Mackie EJ, Halfter W, and Liverani D: Induction of tenascin hl healillg wounds. J Cell Biol 107: 2757-2767, 1988.
9. Mackie EJ, Chiquet Ehrismann R, Pearson CA, Inaguma Y, Taya K, Kawarada Y, and Sakakura T: Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc Natl Acad Sci USA 84: 4621-4625, 1987.
10. Chiquet Ehrismann R, Hagios C, and Schenk S: The complexity in regulating the expression of tenascins. Bioessays 17: 873-878, 1995.
11. Shiraishi T, Kato H, Komada S, Imai H, Hirokawa Y, Kusallo I, Yatani R, and Sakakura T: Tenascin expression and postnatal development ofthe human prostate. Int J Dev Biol 38: 391-395, 1994.
12. Xue Y, Schalken JA, Miller GJ, Ruijter ET, Aalders TW, and Debruyne FMJ: Immunohistochemical determination of in vivo distribution of branching pattern in human adult prostate. [Abstract] J Urol 155(5): P85, 1996.
13. Xue Y, van der Laak JAWM, Latijnhouwers MA, Smedts F, van der Poel HG, de la Rosette JJMCH, Debruyne FMJ, and Schalken JA: Transcient tenascin enhancement is an early event after androgen ablation in rat prostate. [In Press] Urol Res 1998.
14. Xue Y, Li J, Latijnhouwers M, Smedts F, Umbas R, Aalders T, de la Rosette J, Debruyne F, and Schalken J: Expression of periglandular tenascin-C and basement membrane laminin in normal prostate, benign prostatic hyperplasia, and prostate carcinoma. [In Press] Br J Urol 1998.
15. Sage EH and Bornstein P: Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. J Biol Chem 266: 14831-14834, 1991.
16. Freeman MR and Chung LW: Stromal-epithelial interactions: molecular aspects and relevance to benign prostatic hyperplasia. In: Textbook of benign prostatic hyperplasia (Kirby R, McConnell J, Fitzpatrick J, Roehrborn C, andBoyle P, eds). Oxford, ISIS, 1996, pp 57-84.
17. Griffiths K, Coffey D, Cockett A, Di Sant' Agnese A, Ichikawa T, Krieg M, Lee C, McKeehan W, Schalken J, Sciarra F, Steiner G, Sugimura Y, and Yamanaka H: The regulation of prostatic growth. In: Proceedings: The 3rd international consultation on benign prostatic hyperplasia(BPH) (Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, andMurphy G, eds). Paris, S.C.I. pp 73-121, 1995.
18. Isaacs JT, Cussenot O, Jankevicius F, Klocker H, Kubota Y, Morgia G, Rennie P, and Schmits-Drager BJ: Growth regulation of normal and malignant prostatic cells. In: Proceedings of the First International Consultation on Prostate Cancer; 1996 June 20-22; Monaco. (Murphy G, Kriffiths K, Denis L, Khoury S, Chatelain C, and Cockett AT, eds). Manchecourt, S.C.I. pp 31-81, 1997.
19. McNeal JE and Bostwick DG: Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 17: 64-71, 1986.
20. Gleason DF: Histologic grading and clinical staging of prostatic carcinoma. In: Urologic Pathology: The Prostate (Tannehbaum M, ed). Philadelphia, Lea & Gehiger, pp 171-197, 1977.
21. Hiraiwa N, Kida H, Sakakura T, and Kusakahe M: Induction of tenascin in cancer cells by interactions with embryonic mesenchyme mediated by a diffusible factor. J Cell Sci 104: 289-296, 1993.
22. Sakai T, Ohta M, Furukawa Y, Saga Y, Aizawa S, Kawakatsu H and Saito M: Tenascin-C induction by the diffusible factor epidermal growth factor in stromal-epithelial interactions. J Cell Physiol 165: 1 8-29, 1995.
23. Ishihara A, Yoshida T, Tamaki H, and Sakakura T: Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clinical Cancer Res I . 1035-1041, 1995.
24. Ibrahim SN, Lightner VA, Ventimiglia JB, Ibrahim GK, Walther PJ, Bigner DD, and Humphrey PA: Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. Hum Pathol 24: 982-989, 1993.
25. Vollmer G: Biologic and oncologic implications of tenascin-C/hexabrachioll proteins. Crit Rev Oncol Hemat 25: 187-210. 1997.
26. Ibrahim GK, Kerns BJ, MacDonald JA, Ibrahim SN, Kinney RB, Humphrey PA, and Robertson CN: Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues. J Urol 149: 170-173, 1993.
27. Shoji T, Kamiya T, Tsubura A, Hamada Y, Hatano T, Hioki K and Morii S: Tenascin staining positivity and the survival of patients with invasive breast carcinoma. J Surg Res 55: 295-297, 1993.
28. Lightner VA: Tenascin: does it play a role in epidermal morpho-genesis and homeostasis? J Invest Dermatol 102: 273-277, 1994.
29. Yoshida T, Ishihara A, Hirokawa Y, Kusakabe M, and Sakakura T: Tenascin in breast cancer development - is epithelial tenascin a marker for poor prognosis? Cancer Lett 90: 65-73, 1995.
30. Sakr WA, Macoska JA, Benson P, Grignon DJ, Wolman SR, Pontes JE, and Crissman JD: Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res 54: 3273-3277, 1994.
31. Ostor AG: Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 12: 186-192, 1993.
32. Crissman JD, Sakr WA, Hussein ME, and Pontes JE: DNA quantitation of intraepithelial neoplasia and invasive carcinoma of the prostate. Prostate 22: 155-162, 1993.